Park Therapeutics, Inc.

Industry

  • Pharmaceuticals
  • Biotechnology
See more in Biomedtracker

Latest on Park Therapeutics, Inc.

Pink Sheet

BIO Notebook: Waiting On Data, Adjusting To The IRA, And Focusing On All Patients

 
• By Pink Sheet Team

IRA Here To Stay, So Investment Decisions Must Adjust An investor and pharmaceutical executives speaking on a panel at the BIO International Convention in Boston outlined ways in which they have adjus

Scrip

BIO Notebook Day 4: Waiting On Data, Adjusting To The IRA, And Focusing On All Patients

 
• By Pink Sheet Team

IRA Here To Stay, So Investment Decisions Must Adjust An investor and pharmaceutical executives speaking on a panel at the BIO International Convention in Boston outlined ways in which they have adjus

Scrip

Deal Watch: AZ, Alchemab To Study Immune Response For Novel Cancer Targets

 
• By Joseph Haas and John Davis

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. AstraZeneca To Study ‘Elite Controller’